Limits...
Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.

Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE - Br. J. Cancer (2005)

Bottom Line: An altered staining pattern of PPARgamma was observed in high-grade ovarian tumours with PPARgamma being mostly localized in the nuclei with little cytoplasmic immunoreactivity.Western blot analyses showed significant elevation in the expression of immunoreactive PPARgamma in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P < 0.01).These findings suggest an involvement of PPARgamma in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the progression of the disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynaecology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan 250012, PR China.

ABSTRACT
The peroxisome proliferator-activated receptors (PPARs) belong to a subclass of nuclear hormone receptor that executes important cellular transcriptional functions. Previous studies have demonstrated the expression of PPARgamma in several tumours including colon, breast, bladder, prostate, lung and stomach. This study demonstrates the relative expression of PPARgamma in normal ovaries and different pathological grades of ovarian tumours of serous, mucinous, endometrioid, clear cell and mixed subtypes. A total of 56 ovarian specimens including 10 normal, eight benign, 10 borderline, seven grade 1, nine grade 2 and 12 grade 3 were analysed using immunohistochemistry. Immunoreactive PPARgamma was not expressed in normal ovaries. Out of eight benign and 10 borderline tumours, only one tumour in each group showed weak cytoplasmic PPARgamma expression. In contrast, 26 out of 28 carcinomas studied were positive for PPARgamma expression with staining confined to cytoplasmic and nuclear regions. An altered staining pattern of PPARgamma was observed in high-grade ovarian tumours with PPARgamma being mostly localized in the nuclei with little cytoplasmic immunoreactivity. On the other hand, predominant cytoplasmic staining was observed in lower-grade tumours. Significantly increased PPARgamma immunoreactivity was observed in malignant ovarian tumours (grade 1, 2 and 3) compared to benign and borderline tumours (chi2 = 48.80, P < 0.001). Western blot analyses showed significant elevation in the expression of immunoreactive PPARgamma in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P < 0.01). These findings suggest an involvement of PPARgamma in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the progression of the disease.

Show MeSH

Related in: MedlinePlus

(A and B) Haematoxylin and eosin staining of (A) normal ovary, (B) grade 3 serous tumour. PPARγ staining of the same (C) normal ovary (D) and grade 3 serous ovary. Blue arrows indicate nuclear PPARγ staining, while black indicates cytoplasmic staining.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2361744&req=5

fig1: (A and B) Haematoxylin and eosin staining of (A) normal ovary, (B) grade 3 serous tumour. PPARγ staining of the same (C) normal ovary (D) and grade 3 serous ovary. Blue arrows indicate nuclear PPARγ staining, while black indicates cytoplasmic staining.

Mentions: Immunohistochemical expression of PPARγ in epithelial ovarian tumours is described in Table 2. No immunoreactivity of PPARγ was observed in normal ovarian tissues (Figure 1C). Among eight benign and 10 borderline ovarian tumours, weak PPARγ expression was present in only one tumour in each group (Figure 2A). Seven cases of grade 1 ovarian tumours were studied. Four of these showed weak staining and moderate staining was observed in three cases. Both cytoplasmic and nuclear staining was observed (Figure 2B), the distribution being approximately 60% cytoplasmic and 40% nuclear.


Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.

Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE - Br. J. Cancer (2005)

(A and B) Haematoxylin and eosin staining of (A) normal ovary, (B) grade 3 serous tumour. PPARγ staining of the same (C) normal ovary (D) and grade 3 serous ovary. Blue arrows indicate nuclear PPARγ staining, while black indicates cytoplasmic staining.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2361744&req=5

fig1: (A and B) Haematoxylin and eosin staining of (A) normal ovary, (B) grade 3 serous tumour. PPARγ staining of the same (C) normal ovary (D) and grade 3 serous ovary. Blue arrows indicate nuclear PPARγ staining, while black indicates cytoplasmic staining.
Mentions: Immunohistochemical expression of PPARγ in epithelial ovarian tumours is described in Table 2. No immunoreactivity of PPARγ was observed in normal ovarian tissues (Figure 1C). Among eight benign and 10 borderline ovarian tumours, weak PPARγ expression was present in only one tumour in each group (Figure 2A). Seven cases of grade 1 ovarian tumours were studied. Four of these showed weak staining and moderate staining was observed in three cases. Both cytoplasmic and nuclear staining was observed (Figure 2B), the distribution being approximately 60% cytoplasmic and 40% nuclear.

Bottom Line: An altered staining pattern of PPARgamma was observed in high-grade ovarian tumours with PPARgamma being mostly localized in the nuclei with little cytoplasmic immunoreactivity.Western blot analyses showed significant elevation in the expression of immunoreactive PPARgamma in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P < 0.01).These findings suggest an involvement of PPARgamma in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the progression of the disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynaecology, Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan 250012, PR China.

ABSTRACT
The peroxisome proliferator-activated receptors (PPARs) belong to a subclass of nuclear hormone receptor that executes important cellular transcriptional functions. Previous studies have demonstrated the expression of PPARgamma in several tumours including colon, breast, bladder, prostate, lung and stomach. This study demonstrates the relative expression of PPARgamma in normal ovaries and different pathological grades of ovarian tumours of serous, mucinous, endometrioid, clear cell and mixed subtypes. A total of 56 ovarian specimens including 10 normal, eight benign, 10 borderline, seven grade 1, nine grade 2 and 12 grade 3 were analysed using immunohistochemistry. Immunoreactive PPARgamma was not expressed in normal ovaries. Out of eight benign and 10 borderline tumours, only one tumour in each group showed weak cytoplasmic PPARgamma expression. In contrast, 26 out of 28 carcinomas studied were positive for PPARgamma expression with staining confined to cytoplasmic and nuclear regions. An altered staining pattern of PPARgamma was observed in high-grade ovarian tumours with PPARgamma being mostly localized in the nuclei with little cytoplasmic immunoreactivity. On the other hand, predominant cytoplasmic staining was observed in lower-grade tumours. Significantly increased PPARgamma immunoreactivity was observed in malignant ovarian tumours (grade 1, 2 and 3) compared to benign and borderline tumours (chi2 = 48.80, P < 0.001). Western blot analyses showed significant elevation in the expression of immunoreactive PPARgamma in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P < 0.01). These findings suggest an involvement of PPARgamma in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the progression of the disease.

Show MeSH
Related in: MedlinePlus